Valneva SE (VALN) saw an increase of 15% in the premarket. However, the last trading session concluded at $35.4 with a decline of 9.72%.
Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine
On 18th October 2021, VALN reported Phase 3 pivotal trial Cov-Compare of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. The major Phase 3 Cov-Compare study enrolled 4,012 individuals aged 18 and above from 26 trial sites across the United Kingdom. At two weeks after the second vaccination by VALN, VLA2001 showed superiority over AZD1222 (ChAdOx1-S) in terms of geometric mean titer for neutralization antibodies.
In both therapy groups, less than 1% experienced a really concerning adverse event. Participants in the younger age group who received VLA2001 vaccination had an overall safety profile similar to those in the older age group. COVID-19 instances occurred at equal rates in both treatment groups. The absence of any severe COVID-19 cases might mean that both vaccinations employed in the research protected against severe COVID-19.
Cancellation of Ordinary Shares by VALN
On 4th October 2021, VALN reported that upon the expiry of the Company’s liquidity arrangement with Oddo BHF, the Management Board has agreed to cancel all ordinary shares owned by the VALN. Its current share capital is 14,986,674.45 Euros, divided into 99,890,649 ordinary shares and 20,514 preferred shares convertible into ordinary shares.
Positive Phase 2 Results
On 28th September 2021, VALN reported that the company has received further positive Phase 2 findings, including a booster response. 246 healthy individuals aged 18 to 65 were included in the research in the United States. At one month following completion of the main vaccination series, the research accomplished its primary goal. The only goal was to establish that VLA15 was immunogenic across all dosage groups. Antibody titers fell subsequently across both groups, remaining above baseline but demonstrating the requirement for a booster approach. The administration of a booster dosage by VALN generated a significant anamnestic response.
